GenScript and NVIDIA unveil a global competition for AI-driven life sciences startups, enhancing biotech innovation through accelerated connections.

​ Inaugural competition will connect emerging AI life sciences platforms with validation expertise, investors, and ecosystem partners during JPM Week PISCATAWAY, N.J. and SANTA CLARA, Calif., Oct. 8, 2026 /PRNewswire/ -- GenScript Biotech Corporation today announced the GenScript and NVIDIA Life Sciences Startup PitchFest, a global competition for startups applying artificial intelligence to therapeutic discovery and life sciences. The program brings together GenScript's wet lab validation and data generation capabilities and NVIDIA's accelerated computing platforms and startup ecosystem to help selected companies advance AI-driven platforms toward biological proof, investor engagement, and industry visibility.

GenScript, in partnership with NVIDIA, launches Life Sciences Startup PitchFest to connect AI biotech startups with validation, funding, and industry experts.

GenScript Biotech傘下の合成生物学企業Bestzymeが、山東省の済南市に構える自社工場に、甘味タンパク質専用としては世界初とされる自動化生産ラインを導入しました。

Chinese synbio firm Bestzyme, owned by GenScript Biotech, has installed what it says is the world’s first dedicated automated sweet protein production line at its Jinan facility. The rapidly growing sweet protein market has just witnessed a major manufacturing milestone in China. Bestzyme, which is owned by GenScript Biotech, uses precision fermentation to make brazzein, a zero-calorie sweet protein found in the West African Oubli fruit that’s 500-2,000 times sweeter than sucrose and has virtually no impact on blood sugar. It has this week completed the construction of an automated, intelligent production line at its 5,000 sq m facility in Jinan, which it claims is the world’s first commercial manufacturing system specifically designed for sweet proteins. Bestzyme has fully integrated its R&D, mass production and application capabilities for sweet proteins. Once the new line is fully operational, it will be able to churn out 100 tonnes of its brazzein ingredient annually, sold under the Mellia brand. That’s equivalent to the sweetness of 300,000 tonnes of sucrose. The biotech firm now plans to double this capacity within two years through continuous strain iteration and process optimisation, fully equipping the facility for stable, large-scale supply of sweet proteins to food and beverage...

TuneLab, launched by Eli Lilly last week, gives biotech firms access to drug discovery models trained on Lilly's research data.

Those are the adjusted net profits of Genscript Biotech for the first half of 2026, reported on August 17 — a jump of 203 percent year-on-year.

Adjusted net profit surges 203.3% as Gene-to-Protein generates two-thirds of GenScript Life Science Group revenue PISCATAWAY, N.J., Aug. 18, 2026 /PRNewswire/ -- GenScript Biotech Corporation (HKEX: 1548) reported first-half revenue of approximately US$404.2 million on a comparable basis, up 27.3% ...

GenScript Biotech Corporation reported a 27.3% revenue growth for the first half of 2026, fueled by a significant rise in AI drug discovery services. The doubling of this sector underlines the company's robust market position.

Adjusted net profit surges 203.3% as Gene-to-Protein generates two-thirds of GenScript Life Science Group revenue PISCATAWAY, N.J., Aug. 18, 2026 /PRNewswire/ -- GenScript Biotech Corporation (HKEX: 1548) reported first-half revenue of approximately US$404.2 million on a comparable basis,...

GenScript Biotech Corporation reports a stunning 27.3% revenue increase in H1 2026, driven by a surge in AI drug discovery services and strong performance across its business segments.

We acknowledge the Akoya Biosciences support team, especially C. Lassy and M. Hair, for their technical support, GenScript, Biomers and Integrated DNA Technologies for their development of tyramide and HRP oligos, Navinci and ACDBio for their generous donation of reagents utilized in this study, and Parhelia Biosciences for equipment support for automated slide staining on the OpenTrons OT-2. We also thank all members of the Jiang Lab for fruitful discussions and support of this project. We thank K. De Paris and K. Van Rompay for providing SARS-CoV-2-infected NHP tissues. We thank D. Allison (University of Kentucky) for providing basal ganglia FFPE tissues. S.J. is supported in part by NIH DP2AI171139, P01AI177687, R01AI149672, a Gilead’s Research Scholars Program in Hematologic Malignancies, the Bill & Melinda Gates Foundation INV-002704, the Dye Family Foundation, and the Bridge Project, a partnership between the Koch Institute for Integrative Cancer Research at MIT and the Dana Farber/Harvard Cancer Center. J.L.L. is supported by a National Science Scholarship (PhD) from the Agency for Science, Technology and Research, Singapore (BM/NDR/18/003), and is a Schmidt Science Fellow. S.P.T.Y is a MacMillan Family Foundation Awardee of the Life Sciences Research Foundation. Y.Y.Y. is a recipient of the Albert J Ryan...